Quantcast

Latest lung cancer Stories

2014-04-10 12:10:29

Preventing lung cancers from metastasizing to other parts of the body could provide benefit for patients against the leading cause of cancer death Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute (TGen). The hepatocyte growth factor receptor (HGFR/MET) and fibroblast growth factor-inducible 14 (FN14) are proteins associated with the...

2014-04-09 12:31:42

Initiating Phase Ib studies in NSCLC and AML in 2014 BERGEN, Norway, April 9, 2014 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that results from its successful Phase Ia clinical study for lead compound, BGB324, was presented at the American Association of Cancer Research annual conference, which took place on April 5-9, 2014. BGB324 is a first-in-class, highly selective small molecule inhibitor...

2014-04-09 12:31:10

VAL-083 therapy is well tolerated to date; dose limiting toxicity has not been reached after fifth cohort (20mg/m2) VANCOUVER, British Columbia and MENLO PARK, Calif., April 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced an update on its ongoing Phase I/II clinical trial with VAL-083 in the treatment of refractory glioblastoma multiforme (GBM). The company's new data are being presented in a poster entitled, "A Phase I/II Study of VAL-083 in...

2014-04-09 10:43:30

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for...

2014-04-08 08:29:10

Celebrating Monica's Contributions in Memoriam WASHINGTON, April 8, 2014 /PRNewswire-USNewswire/ -- LUNGevity Foundation announces Monica Barlow, formerly director of public relations for the Baltimore Orioles, as the April LUNGevity Hero for her contributions to the fight against lung cancer. An advocate for lung cancer research through her work with LUNGevity for more than four years, Monica was a vital voice for the lung cancer community. Her death in February saddened the lung cancer...

2014-04-08 04:22:04

- Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC - LAUSANNE, Switzerland and LEXINGTON, Mass., April 8, 2014 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

2014-04-07 16:35:29

Women who have radiotherapy for breast cancer have a small but significantly increased risk of subsequently developing a primary lung tumour, and now research has shown that this risk increases with the amount of radiation absorbed by the tissue. Dr Trine Grantzau (MD) told the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna: "We found that for each Gray delivered to the lung as part of radiotherapy for a breast tumour, the relative risk of...

2014-04-07 16:10:23

A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient's body and responses to treatment. Previous versions of the approach, which relies on monitoring levels of tumor DNA circulating in the blood, have required cumbersome and time-consuming steps to customize it to each patient or have not been sufficiently sensitive. Now, researchers at the Stanford University School of Medicine have devised a way to quickly bring...

2014-04-07 12:33:26

New data demonstrates VAL-083 is superior to standard platinum-based chemotherapy in an established in vivo model of non-small cell lung cancer (NSCLC) VANCOUVER, British Columbia, MENLO PARK, Calif. and SAN DIEGO, April 7, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014...

2014-04-07 12:33:09

Next-generation CyberKnife 10.0 Increases Accuracy, Reduces Treatment Time WESTERVILLE, Ohio, April 7, 2014 /PRNewswire/ -- Columbus CyberKnife, a service of Mount Carmel St. Ann's Hospital, recently completed a major upgrade of its cancer treatment technology to the next-generation CyberKnife(®) 10.0 system. http://photos.prnewswire.com/prnvar/20140407/DA98217 CyberKnife is a robotic technology that performs stereotactic body radiation therapy (SBRT), a nonsurgical method of...


Latest lung cancer Reference Libraries

Clinical Lung Cancer
2012-05-14 11:09:55

Clinical Lung Cancer is a peer-reviewed medical journal published bimonthly by the CIG Media Group. It was established in 1999. As of May 2012, the editor-in-chief is David R. Gandara. Gandara is a member of the Board of Directors of the International Association for the Study of Lung Cancer and the Addario Foundation. He has also served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and as secretary-treasurer. He is furthermore a member of...

More Articles (1 articles) »
Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.